Episodes
Friday Jan 08, 2016
Preventing Gestational Diabetes with Myo-Inositol: Ready for Prime Time?
Friday Jan 08, 2016
Friday Jan 08, 2016
With increased emphasis on disease prevention, gestational diabetes (GDM) is worthy of more attention. The incidence is on the rise not only in the United States (U.S.) but worldwide. Complications of GDM such as preeclampsia, cesarean delivery, neonatal hypoglycemia, macrosomia, and birth trauma negatively impact maternal and fetal health. Is a readily available, non-prescription dietary supplement the answer? Recent investigations have examined the use of myo-inositol for GDM prevention, with positive results.
Thursday Nov 19, 2015
The Heart of the Matter – Is EMPA-REG a Game Changer for Diabetes Management?
Thursday Nov 19, 2015
Thursday Nov 19, 2015
The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) study sought to determine the effects of empagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for CVD. Does the evidence from the EMPA-REG OUTCOME study coupled with the other benefits of SGLT2 inhibitors (reduction in weight and blood pressure, mild adverse effects) make empagliflozin the preferred second-line agent from the treatment of type 2 diabetes?